See more : Viking Line Abp (VKGLF) Income Statement Analysis – Financial Results
Complete financial analysis of NutraLife BioSciences, Inc. (NLBS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NutraLife BioSciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Compass Gold Corporation (COGDF) Income Statement Analysis – Financial Results
- Kincora Copper Limited (KCC.AX) Income Statement Analysis – Financial Results
- Sumavision Technologies Co.,Ltd. (300079.SZ) Income Statement Analysis – Financial Results
- Ryman Hospitality Properties, Inc. (RHP) Income Statement Analysis – Financial Results
- SILICON RENTAL SOLUTIONS LIMIT (SRSOLTD.BO) Income Statement Analysis – Financial Results
NutraLife BioSciences, Inc. (NLBS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.nutralifebiosciences.com
About NutraLife BioSciences, Inc.
NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, dietary, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil derived from industrial hemp; tinctures; topical lotions and oils applied directly to the skin to treat pain or inflammation; face creams; massage oils; nutraceutical sprays with CBD as an added ingredient; and pet products. The company also offers other products, such as skincare and sanitizer products. NutraLife BioSciences, Inc. sells its products through nutralifebiosciences.com, as well as through private label distributors, online retailers, and retail outlets. The company was formerly known as NutraFuels, Inc. and changed its name to NutraLife BioSciences, Inc. in March 2019. NutraLife BioSciences, Inc. was incorporated in 2010 and is based in Coconut Creek, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 626.62K | 1.26M | 2.13M | 3.71M | 1.79M | 391.86K | 194.00K | 62.27K | 597.78K | 126.58K |
| Cost of Revenue | 0.00 | 543.03K | 745.93K | 1.54M | 2.21M | 1.06M | 32.82K | 120.90K | 352.32K | 346.96K | 74.83K |
| Gross Profit | 0.00 | 83.59K | 509.85K | 598.13K | 1.50M | 735.13K | 359.03K | 73.10K | -290.05K | 250.82K | 51.75K |
| Gross Profit Ratio | 0.00% | 13.34% | 40.60% | 28.03% | 40.42% | 41.06% | 91.62% | 37.68% | -465.76% | 41.96% | 40.88% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.83K |
| General & Administrative | 0.00 | 4.42M | 2.31M | 3.72M | 3.14M | 20.87M | 1.32M | 1.49M | 1.01M | 1.95M | 405.55K |
| Selling & Marketing | 0.00 | 22.91K | 176.43K | 272.63K | 265.57K | 81.18K | 38.62K | 198.42K | 282.19K | 274.53K | 33.18K |
| SG&A | 0.00 | 4.44M | 2.48M | 3.99M | 3.41M | 20.95M | 1.36M | 1.69M | 1.29M | 2.22M | 438.73K |
| Other Expenses | 0.00 | 114.43K | -53.00 | 58.02K | -34.74K | 1.95K | 60.50K | 55.81K | 52.44K | 45.32K | 768.00 |
| Operating Expenses | 0.00 | 4.56M | 2.48M | 3.99M | 3.41M | 21.02M | 1.42M | 1.74M | 1.34M | 2.27M | 439.50K |
| Cost & Expenses | 0.00 | 5.10M | 3.23M | 5.53M | 5.62M | 22.08M | 1.46M | 1.86M | 1.69M | 2.61M | 514.32K |
| Interest Income | 0.00 | 1.85M | 916.83K | 7.93K | 0.00 | 0.00 | 0.00 | 0.00 | 15.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.85M | 12.80K | 7.93K | 133.75K | 3.34M | 465.14K | 431.10K | 453.25K | 66.96K | 0.00 |
| Depreciation & Amortization | 228.49K | 326.42K | 394.71K | 230.46K | 66.03K | 78.48K | 60.50K | 55.81K | 52.44K | 45.32K | 768.00 |
| EBITDA | 0.00 | -3.65M | -1.58M | -3.77M | -1.87M | -20.21M | -1.43M | -1.61M | -1.57M | -1.97M | -386.98K |
| EBITDA Ratio | 0.00% | -660.65% | -197.68% | -176.65% | -50.51% | -1,128.90% | -255.95% | -832.05% | -2,533.94% | -329.73% | -305.73% |
| Operating Income | 0.00 | -4.47M | -1.97M | -3.40M | -1.91M | -20.29M | -1.06M | -1.67M | -1.63M | -2.02M | -387.75K |
| Operating Income Ratio | 0.00% | -713.77% | -157.12% | -159.14% | -51.36% | -1,133.39% | -271.39% | -860.82% | -2,618.18% | -337.32% | -306.34% |
| Total Other Income/Expenses | 0.00 | -1.35M | -916.89K | -612.03K | -168.49K | -3.34M | -606.04K | -431.10K | -445.28K | -66.96K | 0.00 |
| Income Before Tax | 0.00 | -5.83M | -2.89M | -4.01M | -2.07M | -23.63M | -1.53M | -2.10M | -2.08M | -2.08M | -387.75K |
| Income Before Tax Ratio | 0.00% | -929.99% | -230.13% | -187.82% | -55.90% | -1,319.94% | -390.09% | -1,083.03% | -3,333.20% | -348.52% | -306.34% |
| Income Tax Expense | 0.00 | 1.86M | 12.74K | 65.95K | 168.49K | 3.34M | 465.14K | 431.10K | 445.28K | 66.96K | 0.00 |
| Net Income | 0.00 | -7.68M | -2.90M | -4.07M | -2.07M | -23.63M | -1.53M | -2.10M | -2.08M | -2.08M | -387.75K |
| Net Income Ratio | 0.00% | -1,226.14% | -231.15% | -190.91% | -55.90% | -1,319.94% | -390.09% | -1,083.03% | -3,333.20% | -348.52% | -306.34% |
| EPS | 0.00 | -0.05 | -0.02 | -0.04 | -0.02 | -0.33 | -0.05 | -0.09 | -0.10 | -0.11 | -0.03 |
| EPS Diluted | 0.00 | -0.05 | -0.02 | -0.04 | -0.02 | -0.33 | -0.05 | -0.09 | -0.10 | -0.11 | -0.03 |
| Weighted Avg Shares Out | 0.00 | 164.53M | 146.33M | 113.28M | 87.32M | 71.82M | 33.69M | 23.00M | 21.75M | 18.42M | 15.04M |
| Weighted Avg Shares Out (Dil) | 0.00 | 164.53M | 146.33M | 113.28M | 87.32M | 71.82M | 33.69M | 23.00M | 21.75M | 18.42M | 15.04M |
NutraLife Biosciences Inc. (NLBS) Announces the Company's Financial Fully Reporting Status
Source: https://incomestatements.info
Category: Stock Reports